Come closer: a neurobiological analysis of the prosocial effects of MDMA

This double-blind, placebo-controlled crossover trial (n=24) conducted by Maastricht University explores the prosocial effects of MDMA, oxytocin, and their interaction.

The study aims to understand the neurobiological mechanisms underlying prosocial behaviour induced by MDMA.

Participants, aged 18 to 40 and with MDMA use experience, will receive MDMA, oxytocin, 5-HT1A receptor blocker, or placebos in a crossover design.

The primary outcome measures include empathy and social interaction tasks, with secondary measures assessing oxytocin concentrations and control tasks. Recruitment for this study was completed before February 2024.

The results of the trial can be found here.

Status Completed
Results Published Yes
Start date 14 June 2011
End date 01 January 2012
Phase Not Applicable
Design Blinded
Type Interventional
Generation First
Participants 24
Sex All
Age 18- 40
Therapy No

Trial Details

This trial, led by Universiteit Maastricht, investigates the prosocial effects of MDMA and oxytocin in a double-blind, placebo-controlled crossover study involving 24 participants. The aim is to understand the neurobiological basis of prosocial behaviour induced by MDMA. Participants, aged 18 to 40 with MDMA experience, receive different treatments in a crossover design, with outcomes measured through empathy and social interaction tasks, alongside oxytocin concentration assessments.

NCT Number NL34859.068.10

Sponsors & Collaborators

Maastricht University
Maastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.